**Supplementary Table 1. Demographic and clinical features of the study subjects**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Iron score 0-1+ at biopsy and 0-1+ at transplant, n=64** | **Iron score 3+-4+ at biopsy or transplant, *n*=23** | ***p*** |
| Males/females | 50/14 | 19/4 | not significant |
| Caucasian/non-Caucasian | 56/8 | 19/4 | not significant |
| Age in years, mean±SD | 51.8±11.0 | 54.6±10.0 | not significant |
| Cause of underlying liver disease: chronic viral hepatitis/ alcoholic disease/non-alcoholic steatohepatitis/othera | 25/26/8/18 | 9/13/3/3 | not significant |
| Interval between biopsy and transplant in days, mean±SD | 1053±1099 | 604±636 | 0.02 |
| Iron score at biopsy as 0/1+/2+/3+/4+ | 58/6/0/0/0 | 8/3/4/1/7 | <0.0001 |
| Fibrosis stage at biopsy as 1/2/3/4b | 3/5/17/38 | 0/1/7/15 | not significant |
| History of gastrointestinal bleeding | 29 (45%) | 7 (30%) | not significant |
| History of blood transfusion | 20 (31%) | 9 (39%) | not significant |
| History of intractable ascites | 24 (38%) | 11 (48%) | not significant |
| History of hepatorenal syndrome | 9 (14%) | 5 (22%) | not significant |
| TIPS placement  | 9 (14%) | 5 (22%) | not significant |
| History of hepatocellular carcinoma | 12 (19%) | 7 (30%) | not significant |

aOther causes include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis; multiple causes of chronic liver disease were present in some cases.

bInformation on fibrosis stage was missing for one subject.